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Abstract 
Objectives: Psychotropic medications are frequently used to treat mental health and 
behavioral issues in adolescents and adults with an autism spectrum disorder (ASD). 
Although parents of individuals with ASD frequently take on medication management for 
their child, there is limited literature on parent perspectives of their child’s medication 
use or their views about the health care services they receive, particularly in adulthood. 
The current study examined and compared parents of adolescents and of young adults 
with ASD on their child’s psychotropic medication use and their views about health care 
services. Methods: One hundred parents of adolescents and young adults with ASD 
(ages 12-30 years) completed an online survey about their experience with their child’s 
health care services and medication use. Results: Parents of young adults were less likely 
to use non-pharmacological services before using a psychotropic medication compared to 
parents of adolescents. Parents of young adults were also less likely to believe their 
prescribing health care provider had adequate expertise in ASD and were less satisfied 
with how their prescriber monitored their child’s medication use. Conclusion: Findings 
highlight the need to build capacity among health care providers supporting individuals 
with ASD as they transition into adulthood. There is also a need for improved medication 
monitoring and increased awareness of the different mental health challenges individuals 
with ASD encounter as they age.  
Key words:  autism spectrum disorder; psychotropic medication; young adults; 
adolescents; health care provider, parent experiences 
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Individuals with an autism spectrum disorder (ASD) are frequently prescribed 
psychotropic medications (Coury et al. 2012; Hsia et al. 2013; Logan et al. 2012; Memari 
et al. 2012; Rosenberg et al. 2010; Schubart et al. 2013; Spencer et al. 2013), with over 
three quarters taking psychotropic drugs by the time they reach adulthood (Esbensen et 
al. 2009; Spencer et al. 2013). Despite their widespread use, literature on psychotropic 
medication use in adolescents and young adults with ASD remains limited. Of the few 
studies conducted to date, most have examined medication rates or associated 
demographic and clinical variables (Coury et al. 2012; Esbensen et al. 2009; Lake et al. 
2012; Lake, Weiss, Dergal and Lunsky, in press; Spencer et al. 2013), but not the 
experience of using medication, such as knowledge about or satisfaction with medication 
monitoring.  
Associated mental health issues, and deficits in social, communicative and 
cognitive functioning often impede individuals with ASD from managing their own 
health care (Bruder et al. 2012). Consequently, the responsibility for coordinating and 
managing health care and service provision for their adolescent or adult child, including 
medication use, frequently falls on parents or other caregivers (Bruder et al. 2012; 
Carbone et al. 2010; Howlin et al. 2004; Levy and Perry 2011). Despite this, the little we 
know about parent perspectives regarding their child’s health care and medication use 
comes from studies of children. Generally, this literature suggests that parents are 
dissatisfied with the health care services that their child receives (Carbone et al. 2010; 
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Harrington et al. 2006; Kogan et al. 2008; Liptak et al. 2006; Mackintosh et al. 2012; 
Mitchell and Hauser-Cram 2008).  
We know even less about parent perspectives as individuals with ASD enter 
adulthood, when the needs of patients and families may change (Graetz 2010). This 
transition can be particularly challenging for individuals with ASD, not only in terms of 
physiological changes, but also because of possible changes to residence, education, and 
employment. Additionally, young adults may encounter significant changes in service 
eligibility or accessibility, and some adults may no longer be eligible or have access to 
funded non-pharmacological services or supports. For example, adolescents access 
services through children’s services and the school system, whereas young adults receive 
services within the adult system. Further, young adults must move from the pediatric to 
the adult health care system, where access to health care professionals and trainees who 
have the capacity and expertise to care for individuals with ASD is sparse (Bruder et al. 
2012; Cheak-Zamora et al. 2013; Marrus et al. 2014). Lastly, medication efficacy, 
tolerability, and the reason(s) for prescribing medication or the individual’s psychiatric 
presentation, may also differ between the two groups.  For these reasons, there is a clear 
need to better understand the unique experience of medication use among transitioning 
youth with ASD, and how these experiences differ from younger adolescents. 
In the only study to examine parent perspectives on psychotropic medication use 
among adolescents and adults with ASD, we identified a number of key concerns related 
to medication use and prescribing health care providers (Lake, Milovanov, Sawyer and 
Lunsky, in press). Specifically, our qualitative study found that parents voiced concerns 
about side effects and medication efficacy, as well as concerns related to the low 
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frequency and lack of standardization of medication monitoring. Parents also commented 
on the need for prescribers with expertise in ASD, and for a better integrated system with 
enhanced communication among health care professionals and an interdisciplinary 
approach to treatment. While findings represent an important first step on this topic, 
quantitative research is needed to follow up this qualitative, exploratory study more 
systematically, and with a larger cohort of individuals (Goering and Streiner 1996).  
The current study adds to the limited literature on parent perspectives of 
psychotropic medication use among adolescents and young adults with ASD, and 
expands previous qualitative work using a larger, more diverse sample, divided into two 
subgroups: one of adolescents and the other of young adults with ASD. Our specific 
study objectives include: 1) to describe and compare the number and type of medications 
prescribed in the two groups; and 2) to describe and compare parent perspectives of their 
adolescent or young adult child’s medication use (i.e., reason for medication prescription, 
comfort with medication use, medication side effects, and medication efficacy) and 
parent perspectives regarding health care services received (i.e., expertise issues, use of 
previous services prior to medication use, satisfaction with medication monitoring, 
availability and accessibility of non-pharmacological services).  
Methods 
 The analyses reported here are part of a larger project examining health service 
utilization patterns among individuals with ASD. Participants were recruited across 
Ontario through flyers, websites, and announcements targeted at relevant support groups, 
recreational programs, community agencies and schools. Efforts were made to reach 
families living in all regions of the province, including remote and rural settings where 
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individuals may be marginalized economically or geographically. Parents from this larger 
project who noted that their child had been prescribed psychotropic medication (n=363), 
were invited to participate in a follow-up survey. Parents were deemed eligible if they 
had a child with ASD between 12 and 30 years of age who was currently prescribed at 
least one psychotropic medication. Of the 363 parents contacted, 113 parents completed 
the follow-up survey. Two of these parents had a child under the age of 12, and 11 did 
not have a child who met the recommended Social Communication Questionnaire (SCQ; 
Rutter et al. 2003) research cut-off score of ≥12 (Brooks and Benson 2013).  As a result, 
13 parents were excluded from our analysis resulting in a final sample size of 100 
participants. Respondents were not paid to complete the survey, and participants 
understood that their responses would be linked to their longitudinal data. Individuals 
with ASD were classified as adolescents if they were between 12 and 18 years of age, 
and young adults if they were between 19 and 30 years.  
Participants 
Adolescents with ASD (n= 55) had a mean age of 15.45 years (SD= 1.68), and 
young adults (n= 45) a mean age of 22.2 years (SD= 3.17). Parents had a mean age of 
45.74 years (SD=6.13) and 52.3 years (SD= 4.78), respectively. No significant 
differences were identified among adolescents and young adults in terms mean SCQ 
score. Over three-quarters of adolescents and young adults with ASD were male, most 
were Caucasian, and almost all were living with family (Table 1). No significant group 
differences were observed in terms of gender ratios, ID status, rates of medical or 
psychiatric comorbidity, residence, or ethnicity. Compared to young adults, more 
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adolescents were engaged in structured daytime activities, likely because they were still 
attending mandatory schooling. 
Materials/Procedure 
Background and socio-demographic characteristics, along with information about 
the child’s medication use and experience with prescribing health care providers, were all 
obtained via an online survey. This included information on medication and side effects; 
parent comfort regarding their child’s medication use; satisfaction with prescriber 
medication monitoring; and access to and satisfaction with prescribing health care 
providers. Survey development was informed by findings obtained from a focus group of 
seven parents with an adolescent or adult child prescribed psychotropic medication (see 
“Author” under review, for further detail on the focus group). During this previously 
conducted focus group, parents discussed their experience with medication use and 
interactions with prescribers. Emergent themes from the group helped frame the final 
version of the current survey and also formed the basis of subsequent analyses in the 
present study.  Prior to launching the survey, measures were piloted among participants 
of the focus group and adapted accordingly. The final version of the survey took 
approximately 20 minutes to complete and could be completed online or by phone. All 
parents provided informed written consent after being provided with a detailed 
description of the study. This study received ethics approval through the relevant 
institution’s institutional review board.   
Study Variables 
Demographic and Clinical   
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The following demographic and clinical variables were examined at the 
descriptive level: gender, intellectual disability status (ID), ethnicity, residence, 
structured daily activity, medical comorbidity, psychiatric comorbidity, body mass index 
(BMI) and ASD severity. Individuals were classified as having ID if parents indicated 
that their child had a diagnosis of mild, moderate, severe, or profound ID. ASD symptom 
severity was measured using the SCQ (Rutter et al. 2003), a validated parent-report 
instrument of autism severity.  The SCQ consists of 40 items, based on the Autism 
Diagnostic Interview-Revised (ADI-R), which has demonstrated validity (Chandler et al. 
2007; Howlin and Karpf 2004; Witwer and Lecavalier 2007) and good internal 
consistency, with Chronbach alphas ranging from 0.81-0.93 (Naglieri and Chambers 
2009). Information on BMI was obtained through parent reported child height, weight, 
and pant size/waist circumference. 
Medication and Side Effects 
  Medications were categorized into the following 11 medication classes for 
standard use: a) Psychotropic medications: antidepressants, anxiolytics, atypical 
antipsychotics, typical antipsychotics, stimulants, mood stabilizers, and b) Non-
psychotropic medications: anticonvulsants, antihypertensives, medications for 
gastrointestinal issues, medications for sleep issues (e.g., melatonin, zoplicone), and other 
non-psychotropic medications. Only antihypertensive medications which had evidence 
for the treatment of hyperactivity, inattention, or impulsivity, such as clonidine or 
guanfacine, (Arnsten et al. 2007; Posey et al. 2004) were categorized as psychotropic 
medication, as was done by others (Aman et al. 2003; Lake et al., in press; Langworthy-
Lam et al. 2002; Logan et al. 2012). Similarly, the distinction between mood stabilizers 
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and anticonvulsants was made by classifying medications (e.g., valproate and 
carbamazepine) as mood stabilizers for all individuals who did not have a diagnosis of 
seizure disorder, as has been done previously (Esbensen et al. 2009; Lake et al. 2012; 
Spencer et al. 2013). Parents were also asked if their child had experienced side effects as 
a result of medication use (yes, no, don’t know), what side effects their child had 
experienced (open-ended), and what effect, they felt, medication (s) had on their child’s 
psychological wellbeing (good or mostly good, neutral, bad or mostly bad). Medication 
side effects were then classified into the following categories: metabolic (e.g., weight 
gain, increased appetite, increased blood pressure, increased blood sugar), cardiac (e.g., 
increased heart rate), movement (e.g., muscle stiffness, tics, involuntary movements), 
fatigue/sleep (e.g., lethargy, somnolence, sedation, nightmares), general neurological 
change (e.g., headaches, dizziness, disorientation, slowed down, subdued), behaviour 
change (e.g., mania, fixed thoughts, aggression, anxiety, irritable, depression), serious 
neurological events (e.g., seizure), endocrine (e.g., lactation, breast growth), 
dermatological (e.g., acne), gastrointestinal (e.g., constipation, loose bowels, nausea), 
hematological (e.g., nose bleed, low iron), temperature dysregulation (e.g., heat 
sensitivity, fever), weight loss, thirst, sexual (e.g., sexual dysfunction), and genitourinary 
(e.g., urinary retention). Classifications were based on literature on medication side 
effects (AHFS, 2014; Matson et al., 1998), and side effects were independently verified 
and coded by two authors (VV, AS). 
Parent Views about Medication  
 We examined the following variables regarding parents’ views about medication: 
reason(s) for medication prescription (targeted symptoms) and parental ratings of their 
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comfort with medication(s) (comfortable, neutral, uncomfortable). Targeted symptoms 
were classified into the following four behavior or mental health categories based on 
parent-report of why their child was prescribed medication: externalizing behaviours 
(e.g., repetitive, aggressive, oppositional or self-injurious behavior, ADHD symptoms), 
internalizing problems (e.g., anxiety, depression, bipolar), social issues (e.g., social 
appropriateness, eye contact, understanding emotional cues), and psychotic disorder (e.g., 
schizophrenia, schizoaffective disorder).  
Parent Views about Health Care Services 
  We examined the following variables related to parents’ views about health care 
services: prescriber expertise in ASD (yes/no), use of previous supports or services prior 
to medication use (yes/no), satisfaction with how medication is monitored by prescribing 
health care provider (satisfied, neutral or dissatisfied), and role of non-pharmacological 
services (health care provider/school/service suggested medication, no access/availability 
of non-pharmacological services, non-pharmacological services not/partially working). 
Data Analysis 
 Descriptive statistics were used to describe demographic and clinical information 
for the sample (numbers and percentages for count data and means and standard 
deviations for continuous variables). Bivariate analyses were conducted to compare the 
views of parents of adolescents versus those of young adults with ASD in terms of their 
child's medication use, the type and number of medications their child was prescribed, 
and their views about health care services. Statistical analyses were conducted using 
SPSS version 20.0.   
Results 
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Medication and Side Effects 
As shown in Table 2, antipsychotic medications were the most commonly 
prescribed medication among the total sample (56%), and among adolescents specifically 
(54.5%). Young adults (68.9%) were significantly more likely to use antidepressant 
medications than adolescents (41.8%), χ2(1)=7.3, p=0.007, and adolescents (40.0%) were 
more likely to use stimulants than young adults (15.6%), χ2(1)=7.18, p=0.007. Parents of 
adolescents (85.5%) were significantly more likely to have a child prescribed 
psychotropic medication for externalizing behaviours compared to parents of young 
adults (61.4%), χ2(1)=7.52, p=0.006.  Forty percent of young adults used non-psychotropic 
medications in addition to a psychotropic medication, while only 25% of adolescents 
used these medications. On average, young adults were prescribed more psychotropic and 
non-psychotropic medications (M = 2.27) than adolescents (M = 1.91), and almost half of 
all adolescents (43.7%) and young adults (48.9%) were taking two or more psychotropic 
medications concurrently.  
 Parents of adolescents (70.9%) were more likely to report that their child had 
experienced side effects as a result of psychotropic medication use compared to parents 
of young adults (48.8%), χ2(2)=7.27, p=0.003 (Table 4). Specifically, parents of 
adolescents were more likely to report that their child had experienced weight loss as a 
side effect of medication use, and although not statistically significant, metabolic side 
effects were also more common among adolescents (30.9%) than young adults (19.5%) 
(Table 3), Almost half of the total sample fell in either the overweight (24.4%) or obese 
(20.0%) BMI category, and nearly one-quarter of parents of young adults reported that 
they did not know if their child had experienced medication side effects, compared to 
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only 6% of adolescents. Most parents in both groups (adolescents=77.4%; young 
adults=80.0%) believed medication had a good/mostly good effect on their child’s 
behavior or mental health, and approximately one third of parents of both adolescents and 
young adults reported that they were comfortable with the medication(s) their child was 
taking.  
 Parent Views about Health care Services  
 Most parents of adolescents (80.0%) and young adults (84.4%) indicated that their 
child’s prescriber monitored their child’s medications 2-3 times a year or less. Parents of 
young adults were less satisfied with how their prescriber monitored their child’s 
medication, χ2(1)=4.48, p=0.03, and were less likely to feel their prescriber had adequate 
expertise in ASD, χ2(1)=5.14, p=0.02. Compared to parents of adolescents, parents of young 
adults were also less likely to use previous supports or services before trying medication 
(p=0.05). Finally, almost one-third of adolescents and one-quarter of young adults 
reported that non-pharmacological services or supports were not or only partially 
working for behavior or mental health problems (Table 5).  
Discussion 
 This is the first study to examine parent perspectives of their child’s psychotropic 
medication use by comparing the experiences of parents of adolescents to parents of 
young adults transitioning out of the pediatric health care system. Findings highlight key 
differences between the experiences of adolescents and their parents and the experiences 
young adults and their parents. The two groups differed in terms of their medication 
profiles, medication side effects, satisfaction with care from prescribers, and relative use 
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of other health care services. Differences point to target areas for intervention and 
opportunities for intervention with youth and their families prior to adulthood.   
Consistent with previous studies (Aman et al. 2005; Mandell et al. 2008), the most 
frequent reason for a medication prescription among adolescents was externalizing 
behaviours, while internalizing problems were more common among young adults. 
Medication profiles reflected these differences with stimulant medications more 
frequently prescribed among adolescents (adolescents=40%; young adults=16%), and 
antidepressants among young adults (adolescents=42% young adults=69%).  Better 
evidence of the efficacy of antidepressant use in adults with ASD may in part explain this 
difference (Doyle & McDougle, 2012).  
In terms of medication side effects, parents of adolescents were more likely to 
report that their child had experienced side effects compared to parents of young adults. 
This finding may reflect differences in the metabolism of specific medications in 
adolescents versus adults (Ginsberg et al. 2002), but it may also be that with chronic 
medication use, parents of young adults become less aware of medication side effects 
compared to parents of adolescents. Another possibility is that the greater number of side 
effects observed in adolescents is linked to higher stimulant use which is associated with 
more frequent reports of weight loss and movement abnormalities. In our study, nearly 
one quarter of parents of young adults reported that they did not know if their child was 
experiencing medication side effects. The mean number of medications for young adults 
(2.27) was higher than for adolescents (1.91) in the current study, perhaps making it 
difficult to discern side effects.  
One of the most concerning side effects of medication use is weight gain. In the 
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current study, almost half of all young adults and adolescents were overweight or obese, a 
finding consistent with studies of young adults with ASD (Eaves and Ho 2008), but 
higher than what has been reported in studies of children with ASD (Zuckerman et al. 
2014). This rate is also more than double the rate among the general adolescent 
population (Roberts et al. 2012). Similarly, almost one third of adolescents reported 
metabolic side effects, which is not surprising given that 84% were prescribed 
antipsychotic drugs. More specifically, 71% of these individuals were prescribed atypical 
antipsychotic medications (e.g., Risperidone, Olanzapine Aripiprazole, Paliperidone), all 
medications with known metabolic effects. While medication use is one contributor of 
obesity, there are a number of other factors that may also contribute, including restrictive 
eating patterns, motor impairments, cognitive impairments, and medical comorbidities, 
all common among individuals with ASD (Egan et al. 2013; Zuckerman et al. 2014). 
Alongside high rates of metabolic side effects, parents of adolescents were more likely to 
report weight loss or decreased appetite as a result of medication use, however this may 
be due to greater use of stimulants among adolescents. For these reasons, there is an even 
greater need for prescribers to monitor for metabolic side effects when prescribing 
psychotropic medications that have the potential to cause weight gain or loss among 
individuals with ASD.  
  In the current study, approximately 80% of individuals using medication had 
their medication monitored only two to three times a year or less, despite almost half of 
the sample taking two or more psychotropic medications concurrently. This finding is 
concerning in the context of recent guidelines for the primary care of persons with 
developmental disabilities which recommend medication monitoring every 3 months 
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(Sullivan et al. 2011). Guidelines developed by the National Institute for Health and Care 
Excellence (NICE; NICE 2012) suggest medication monitoring every two to three weeks 
during the initiation phase of a psychotropic medication prescription, but do not specify 
ongoing monitoring requirements.  Canadian guidelines for the monitoring of 
antipsychotic medications recommend monitoring antipsychotic medications every three 
to six months, and more frequently in vulnerable populations, including individuals with 
ASD (Cohn and Semyak 2006; McCracken 2005). Individuals with ASD are more 
sensitive to medication side effects, adding to the need to carefully monitor medication 
use in this population (McCracken 2005). This may be linked to the finding that some 
parents were dissatisfied with how their child’s medications were monitored. 
Unfortunately, this problem may be compounded by challenges finding a prescribing 
health care provider who is comfortable or familiar prescribing and monitoring 
medications for individuals with ASD, especially in adulthood. Together, findings 
highlight the need for prescribers to monitor psychotropic and non-psychotropic 
medications, particularly as individuals with ASD age and may be at greater risk for 
comorbid conditions and the use of multiple medications. 
Compared to parents of adolescents, parents of young adults with ASD were 
significantly less likely to believe their prescriber had adequate expertise in ASD and also 
felt less satisfied with how their prescriber monitored their child’s medication. This 
finding is particularly concerning given heightened rates of comorbid psychiatric (Doshi-
Velez et al. 2014; Kohane et al. 2012) and medical problems (Bauman 2010; Doshi-
Velez et al. 2014; Kohane et al. 2012) among adults with ASD. As individuals age the 
likelihood of developing a comorbid medical problem increases, and although our sample 
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of adults was relatively young, almost half of them were prescribed non-psychotropic 
medications in addition to a psychotropic medication prescription. Going forward it will 
be important to understand why young adults are prescribed non-psychotropic 
medications (e.g., to counteract effect of psychotropic drugs or for health issues), as well 
as how best to support the complex medical and psychiatric needs of this population.  
Findings suggest that the pathway to medication use may be different for 
parents of young adults compared to adolescents. Not only did the medication profiles of 
adolescent and young adults with ASD differ, but so did their experiences with health 
care services. There are a number of possible explanations for these differences – results 
could be explained by a cohort effect where older parents simply have different 
experiences than younger parents. It could also be the case that when parents start their 
child on medication later in life, they are less likely to pursue other services and supports. 
Or it may be that parents of young adults experience greater difficulty finding and 
accessing services or supports for their adult child once they are no longer eligible for 
services funded through the educational or pediatric health care systems. Despite the fact 
that a number of evidence-based non-pharmacological practices for individuals with ASD 
exist, including intensive behavior intervention, positive behavior supports, and cognitive 
behavior therapy (Perry and Condillac 2003), medication may be the only readily 
available, accessible, and funded treatment option for many young adults. Other studies 
have shown that there may be barriers to accessing appropriate non-pharmacological 
services once individuals with ASD reach adulthood (Gerhardt & Lainer, 2011; Shattuck, 
Wagner, Narendorf, Sterzing & Hensley 2011; Shattuck et al., 2012). Regardless of age, 
it is important that all individuals with ASD follow guidelines which argue for access to 
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psychosocial interventions prior to medication use for the treatment of mental health 
issues among individuals with ASD (NICE 2012; Sullivan et al. 2011).  
The study is subject to a number of limitations. First, findings are based on parent 
report data, and we did not have access to corroborating sources to validate diagnoses or 
medications. However, only individuals with an SCQ score at or above the recommended 
cutoff (≥12; Brooks and Benson 2013) were included in these analyses. It is possible that 
some individuals in this study would not meet full DSM-V criteria for ASD; however, 
previous studies suggest that parent-reported ASD diagnoses produce prevalence 
estimates comparable to population-based studies using validated medical records or 
diagnostic tools (CDC 2012, 2013; Kogan et al. 2008). While we recognize that our 
sample may not be representative of all individuals with ASD, most individuals with 
ASD tend to reside with their parents well into adulthood (Howlin and Moss 2012), thus 
findings from parent report surveys have considerable value in understanding adolescents 
and young adults with ASD.  In addition, the authors did not have access to longitudinal 
medication information. This information could help clarify, for example, the relationship 
between satisfaction with medication monitoring and medication side effects, efficacy, 
comfort, or prescriber expertise. Similarly, despite its constraints, a number of studies 
have used similar survey-based methods to study this population (Blumberg et al. 2013; 
Mazurek 2013; Mazurek et al. 2011; Montes and Halterman 2007) including the 2011-
2012 National Survey of Children’s Health (CDC 2013) and the 2011-2012 National 
Health Interview Survey (CDC 2012).  
Conclusions 
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 In the current study, young adults with ASD accessed fewer non-pharmacological 
supports before trying a medication prescription, and parents felt their prescribers had 
less expertise in ASD. This may suggest that young adults face particular challenges 
accessing services and supports once they age out of the pediatric system—a concerning 
finding given heightened rates of comorbid psychiatric disorders and medication use in 
adulthood.  Given high rates of medication use observed in this population, an important 
next step will be to identify ways to support and train health care providers in obtaining 
the expertise to effectively care for these individuals. This will also involve ensuring that 
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Clinical Significance: This is the first study of adolescents and young adults with ASD 
to examine parent perspectives of their child’s psychotropic medication use and their 
views about health care services.  Findings identified that compared to parents of 
adolescents; parents of young adults were less likely to access non-pharmacological 
services and supports prior to initiating a psychotropic medication. Parents of young 
adults were also less likely to feel their prescriber had expertise in ASD, and were less 
satisfied with how their child’s medications were monitored. This may suggest there are 
limited non-pharmacological services for young adults with ASD, and also highlight the 
need to build capacity among clinicians providing care to young adults where there are 
fewer mental health professionals who feel equipped to provide care to this population. 
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Table 1. Descriptive statistics of sample (n=100). 
 
Parameter Adolescents (12-18) 
(n=55) 
% 





Gender (male) 83.6 75.6 χ2(1) = 1.01, p= 0.32 
Intellectual disability (yes) 54.0 50.0 χ2(1) = .15, p= 0.70 
Caucasian 87.3 82.2 χ2(1) = .50, p= 0.48 
Living with family 100.0 92.5 χ2(1) = 4.03, p= 0.05 
Structured activity 98.2 75.6 χ2(1) = 12.00, p= 0.001*** 
Medical comorbidity 33.0 33.0 χ2(1) = .004, p= 0.95 
Psychiatric comorbidity 63.3 73.6 χ2(1) = 1.07, p= 0.30 
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Medication drug classes 
Antipsychotic 54.5  57.8  χ2(1)=0.11, p=0.75 
Anxiolytic 7.3  6.7  χ2(1)=0.01, p=0.91 
Antidepressant 41.8  68.9  χ2(1)=7.30, p=0.01** 
Mood Stabilizer 0  4.4  χ2(1)=2.49, p=0.11 
Stimulant 40.0  15.6  χ2(1)=7.18, p=0.01** 
Non-psychotropic medication 25.5  40.0  χ2(1)=2.41, p=0.12 
Number of medications  
Mean number of total 
medications 
  1.91 
(1.08) 
  2.27 
(1.53) 
t(98)=1.37, p=0.17 
2 concurrent psychotropic 
medications 
43.6  48.9   
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Table 3. Type and number of medication side effects associated with adolescents and 









 % Rank % Rank  
Medication side effects 
   Yes 70.9  48.8  χ2(2)=7.27, p=.003** 
   No 23.6  29.3  
   Don’t know 5.5  22.0  
Top 5 most commonly reported medication side effects 
Metabolic  30.9 1 19.5 2  
Fatigue/sleep 23.6 2 22.0 1  
Weight loss 16.4 3 2.4 -  
Behaviour change 16.4 3 12.2 4  
Movement 14.5 4 7.3 5  
General neurological change 9.1 5 17.1 3  
Gastrointestinal 9.1 5 7.3 5  
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Reason for medication prescription  
Externalizing behaviours 85.5 61.4 χ2(1)=7.52, p=0.006** 
Internalizing problems  70.9 84.1 χ2(1)=2.38, p=0.12 
Social issues 12.7 11.6 χ2(1)=0.03, p=0.87 
Psychotic disorder 5.5 9.1 χ2(1)=0.49, p=0.48 
Comfort with medication use 
   Comfortable 36.4 33.3 
χ2(3)=2.49, p=0.48 
   Neutral 49.1 40.0 
   Uncomfortable 3.6 8.9 
   Other 10.9 17.8 
Medication efficacy 
   Good or mostly good 77.4 80.0 
χ2(2)=0.44, p=0.80    Neutral 17.0 12.5 
   Bad or mostly bad 5.7 7.5 
*p ≤  0.05, **p ≤  0.01, ***p ≤  0.001 
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Table 5. Parent views about health care services associated with adolescents and young 









Views about prescribers 
 
Prescriber expertise in ASD 
   Yes 69.1 43.9 
χ2(1)=5.14, p=0.02* 
   No 30.9 56.1 
Satisfaction with prescriber medication monitoring 
   Satisfied 53.7 38.1 
χ2(1)=4.48, p=0.03* 
   Neutral or Dissatisfied 46.3 67.9 
Views about services 
 
Use of non-pharmacological services prior to initiating medication use 
   Yes 81.8 64.4    χ2(1)=3.88, p=0.05* 
Role of non-pharmacological services 




  Non-pharmacological supports     
not or only partially working 
32.7 24.4 
  Healthcare provider, school, or 
other service suggested 
medication 
51.9 48.8 
  Other  13.5 17.1 
*p ≤ 0.05, **p ≤  0.01, ***p ≤ 0.001 
 
